scispace - formally typeset
Open AccessJournal ArticleDOI

Drug abuse in schizophrenic patients: clinical correlates and reasons for use.

Reads0
Chats0
TLDR
Schizophrenic patients who abuse drugs may represent a subgroup of patients with better prognoses and less severe clinical characteristics of schizophrenia, but their drug abuse may adversely affect global outcome.
Abstract
Objective: This study aimed to 1) determine substance abuse prevalence and preference in a diverse sample ofschizophrenic, schizoaffective, and schizophreniform inpatients, 2) cornpare drug-abusing and non-drug-abusing patients on demographic and clinical variables during the acute and stabilization phases of their hospital course, and 3) obtain data from patients on reasons for drug abuse and on acute state-related changes during periods of intoxication. Method: Eighty-three psychotic inpatients consecutively admitted to a New York City teaching hospital were evaluated. Sixty-eight had schizophrenia, 12 had schizoaffective disorder, and three had schizophreniforrn disorder diagnosed according to the Structured Clinical Interview for DSM-III-R. Each patient received ratings on the Brief Psychiatric Rating Scale, the Global Assessment Scale, and the Scale for the Assessment of Negative Symptoms at admission and at discharge, an evaluation of premorbid adjustment, and an extensive interview on drug and alcohol use. Results: Forty (48%) of the patients received diagnoses of drug or alcohol abuse or dependence. The drug-abusing patients primanly used cannabis (N=26), alcohol (N=2 1), and cocaine (N= I 4) and reported that they abused drugs to get “high, “ to relieve depression, and to relax. They had significantly fewer positive and negative symptoms at discharge, better sexual adjustment and worse school performance during adolescence, and more family histories ofdrug abuse than the non-d rugabusing patients. Conclusions: Schizophrenic patients who abuse drugs may represent a subgroup of patients with better prognoses and less severe clinical characteristics of schizophrenia, but their drug abuse may adversely affect global outcome.

read more

Citations
More filters
Journal ArticleDOI

MAM (E17) rodent developmental model of neuropsychiatric disease: disruptions in learning and dysregulation of nucleus accumbens dopamine release, but spared executive function.

TL;DR: The predominant behavioral-cognitive feature of the MAM model is a learning impairment that is evident in acquisition of executive function tasks as well as basic Pavlovian associations, and MAM animals also have dysregulated terminal DA release, which may contribute to observed behavioral differences.

The Longitudinal Impact of Intrinsic Motivation on Substance Use Severity in Schizophrenia and its Patterns in Men and Women

TL;DR: Evidence was found suggesting longitudinal intrinsic motivation change is a salient incremental predictor of reductions in patient’s alcohol/ drug use severity, above and beyond the effects of age, illness chronicity, overall psychopathology, comorbidity status, and phase 1 randomization medication effects.
Journal ArticleDOI

Poids de la comorbidité addictive dans le risque d’observance partielle au traitement médicamenteux et de rechute dans la schizophrénie

TL;DR: La comorbidite addictive a un poids significatif (p Conclusion Le poids des addictions comorbides represente entre 1/5 et 1/3 des facteurs en jeu dans l’observance and le risque de rechute des patients souffrant de schizophrenie.
Journal ArticleDOI

Drugs and Psychosis Project: a multi-centre European study on comorbidity.

TL;DR: Cross-cultural differences in the sociodemographic characteristics of the comorbid patient population give a better insight into this heterogenous group of psychotic patients.
Journal ArticleDOI

Psychosis and substance abuse: cause, effect or coincidence?

TL;DR: In this article, a survey of 38 consecutively admitted patients with DSM-III-R functional psychoses was conducted and a semi-structured substance abuse interview was administered and a urine specimen for drug metabolite screening requested.
References
More filters
Journal ArticleDOI

The Brief Psychiatric Rating Scale

TL;DR: The Brief Psychiatric Rating Scale (BRS) as mentioned in this paper was developed to provide a rapid assessment technique particularly suited to the evaluation of patient change, and it is recommended for use where efficiency, speed, and economy are important considerations.
Journal ArticleDOI

The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance.

TL;DR: The relative simplicity, reliability, and validity of the GAS suggests that it would be useful in a wide variety of clinical and research settings.
Journal ArticleDOI

Negative Symptoms in Schizophrenia: Definition and Reliability

TL;DR: The developed Scale for the Assessment of Negative Symptoms has excellent interrater reliability and the five symptom complexes defined by the scale have good internal consistency, which indicates that the conceptual organization of the scale is also cohesive.
Journal ArticleDOI

One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites.

TL;DR: One-month prevalence results were determined from 18571 persons interviewed in the first-wave community samples of all five sites that constituted the National Institute of Mental Health Epidemilogic Catchment Area Program as mentioned in this paper.
Journal ArticleDOI

Measurement of Premorbid Adjustment in Chronic Schizophrenia

TL;DR: The Premorbid Adjustment Scale has been found to be useful in identifying patients likely to become chronically hospitalized or at high risk for readmission, and may also serve as a possible predictor of patients with brain abnormalities on a computerized tomography scan.
Related Papers (5)